These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 21606435)

  • 1. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis.
    Tirelli U; Berretta M; Bearz A; Carbone A
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1355-6. PubMed ID: 22195374
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
    Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
    J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evaluating the effectiveness of drugs. "The full potential of a therapy is often only clear after a number of years" (interview by Helmut Laschet)].
    Pfundner H
    MMW Fortschr Med; 2010 Dec; 152(51-52):10. PubMed ID: 21294362
    [No Abstract]   [Full Text] [Related]  

  • 5. Era of personalized medicine may herald end of soaring cancer costs.
    Keogh B
    J Natl Cancer Inst; 2012 Jan; 104(1):12-3, 16-7. PubMed ID: 22173586
    [No Abstract]   [Full Text] [Related]  

  • 6. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical studies in oncology--a challenge for clinical and academic pathology].
    Röcken C
    Dtsch Med Wochenschr; 2013 May; 138(20):1073-6. PubMed ID: 23670265
    [No Abstract]   [Full Text] [Related]  

  • 8. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 9. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 11. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Japanese universal health care faces a crisis in cancer treatment.
    Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
    Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving the outcomes: developing cancer therapeutics.
    Utku N
    Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 17. Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology.
    J Clin Oncol; 1997 Feb; 15(2):853-9. PubMed ID: 9053513
    [No Abstract]   [Full Text] [Related]  

  • 18. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
    Marino P; Bertucci F; Gonçalves A; Seror V
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 20. The era of cancer discovery.
    Cantley LC; Baselga J
    Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.